Abeid Mohamed, Kaddah Tarek, Zaitoun Nahla A, Alsamman Mohd Amer
Faculty of Medicine, Cairo University, Cairo, Egypt.
Warren Alpert School of Medicine, Brown University, Providence, RI, USA.
Obes Surg. 2019 Jul;29(7):2087-2091. doi: 10.1007/s11695-019-03848-x.
Intragastric balloons are used as a treatment for obesity. Much of the data collected on balloons had been in the context of clinical trials in academic medical centers or as a bridge to bariatric surgery in obesity centers. The aim of this study was to investigate the efficacy and safety of balloon treatment in private practice.
This is an interventional study.
The study included 1600 patients.
The study was conducted at the ElKatib Hospital.
This was a retrospective analysis of 6-month weight loss data and balloon-related complications of patients referred to a private center for obesity treatment.
The assessment was carried out by obtaining full patients' history (personal history, present illness, and previous drug history and operations). Laboratory work was done in the form of CBC, blood sugar, and viral markers. Bioenterics Intragastric Balloon (BIB) silicone balloon was used, filled with saline plus methylene blue dye with a volume ranging from 400 to 700 ml. The gained measures were analyzed by using SPSS program, and paired t test and chi-square test were used to compare between groups.
A total of 1600 patients were included (368 male (23%) and 1232 female (77%)) with mean age 34.1 ± 10.354, mean body weight 112.45 ± 26.24, and mean body mass index (BMI) 40.32 ± 8.17. There were 46 patients younger than 18 years and 12 patients older than 60 years. There were 109 patients with a BMI ranging from 25 to < 35 and 737 patients with a BMI ≥ 40 kg/m. A total of 1567 patients who attended weight consultation had a mean weight loss 17.35 ± 11.07 from intragastric balloon implantation. Thirty-three patients from the total sample were not weighted after the removal of the balloon (dropped out). Percentage excess weight loss (% EWL) = 100% × (baseline absolute weight (AW)-last weight)/(baseline AW-initial body weight (IBW)) was found, and weight loss of more than 10% was considered significant. About 49.3% of patients showed significant weight loss > 10%, 24.7% of patients showed weight loss > 20%, while 26% of patients showed no significant weight loss < 10%.
Intragastric balloons on their own, with an intensive lifestyle program and supportive consultations, resulted in safe and short-term substantial weight loss, and may fill the therapeutic gap between pharmacotherapy and surgery.
胃内球囊被用作肥胖症的一种治疗方法。关于球囊收集的大部分数据是在学术医疗中心的临床试验背景下，或者作为肥胖症中心减肥手术的桥梁。本研究的目的是调查在私人诊所进行球囊治疗的疗效和安全性。
这是一项干预性研究。
该研究纳入了1600名患者。
研究在ElKatib医院进行。
这是一项对转诊至一家私人肥胖治疗中心的患者的6个月体重减轻数据和与球囊相关并发症的回顾性分析。
通过获取患者的完整病史（个人史、现病史、既往用药史和手术史）进行评估。实验室检查以全血细胞计数、血糖和病毒标志物的形式进行。使用Bioenterics胃内球囊（BIB）硅胶球囊，填充生理盐水加亚甲蓝染料，体积范围为400至700毫升。使用SPSS程序对获得的测量数据进行分析，并使用配对t检验和卡方检验进行组间比较。
共纳入1600名患者（男性368名（23%），女性1232名（77%）），平均年龄34.1±10.354岁，平均体重112.45±26.24千克，平均体重指数（BMI）40.32±8.17。有46名患者年龄小于18岁，12名患者年龄大于60岁。有109名患者的BMI范围为25至<35，737名患者的BMI≥40千克/平方米。总共1567名参加体重咨询的患者在植入胃内球囊后平均体重减轻了17.35±11.07千克。在取出球囊后，总样本中有33名患者未称重（退出）。计算得出超重减轻百分比（%EWL）=100%×（基线绝对体重（AW）-末次体重）/（基线AW-初始体重（IBW）），体重减轻超过10%被认为是显著的。约49.3%的患者体重显著减轻>10%，24.7%的患者体重减轻>20%，而26%的患者体重减轻不显著<10%。
胃内球囊结合强化生活方式计划和支持性咨询，可实现安全且短期的显著体重减轻，并可能填补药物治疗和手术之间的治疗空白。
